New Perspectives in Colorectal Cancer

Colorectal cancer is the third most common cancer and the third leading cause of cancer mortality in the United States. Until recently, chemotherapy with FOLFOX or FOLFIRI was the mainstay of treatment. However, in the past years, the addition of new biologic agents targeting epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGR) in combination with various chemotherapy regimens has significantly improved progression-free survival and overall survival in patients with this disease. Welcome as these developments are, understanding the new regimens, evaluating ever-increasing clinical data, and incorporating new advances into existing therapeutic strategies, requires considerable time and effort on the part of clinicians if they are to be able to offer their patients the best therapy available.

The purpose of this activity is to provide education on the latest advances in the treatment of colorectal cancer.

Available until December 31, 2010, this activity offers:
Physicians: 1.0 AMA PRA Category 1 Credit^™
Nurses: 1.1 contact hours

This activity is jointly sponsored by:

This activity is supported by an educational grant from Roche.
 

 

[Back to top]

[Back to Activity Home]